Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30913037.
- Also identified by DOI 10.1172/JCI126912 and PMC identifier 6597217.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Identifying non-addictive opioid medications is a high priority in medical sciences, but μ-opioid receptors mediate both the analgesic and addictive effects of opioids. We found a significant pharmacodynamic difference between morphine and methadone that is determined entirely by heteromerization of μ-opioid receptors with galanin Gal1 receptors, rendering a profound decrease in the potency of methadone. This was explained by methadone's weaker proficiency to activate the dopaminergic system as compared to morphine and predicted a dissociation of therapeutic versus euphoric effects of methadone, which was corroborated by a significantly lower incidence of self-report of "high" in methadone-maintained patients. These results suggest that μ-opioid-Gal1 receptor heteromers mediate the dopaminergic effects of opioids that may lead to a lower addictive liability of opioids with selective low potency for the μ-opioid-Gal1 receptor heteromer, exemplified by methadone.
Medical subject headings
- Analgesics, Opioid
- Methadone
- Morphine
- Protein Multimerization
- Receptor, Galanin, Type 1
- Receptors, Opioid, mu